EED226 |
Catalog No.GC19130 |
EED226은 배아 외배엽 발달(EED) 시 K27me3-포켓에 결합하고 이종이식 마우스 모델에서 강력한 항종양 활성을 나타내는 폴리콤 억제 복합체 2(PRC2) 억제제입니다. EED226은 강력하고 선택적이며 경구 생체이용 가능한 EED 억제제입니다. EED226은 H3K27me0 펩티드가 시험관 내 효소 분석에서 기질로 사용될 때 23.4nM의 IC50으로 PRC2를 억제합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2083627-02-3
Sample solution is provided at 25 µL, 10mM.
EED226 is a potent, selective, and orally bioavailable embryonic ectoderm development (EED) inhibitor with an IC50 of 22 nM.
EED226 is a highly potent, efficient and selective inhibitor of EZH2 and EZH1 evaluated against a broad range of epigenetic and non-epigenetic targets. It potently reduces global H3K27Me3 mark in cells and demonstrates selectively cell killing effects in cells carrying a heterozygous Y641N mutation. EED226 has moderate permeability as the measured in Caco-2 cells at A→B=3.0x10-6 cm/s, with an efflux ratio at 7.6[1].
EED226 induces robust and sustained tumor regression in EZH2MUT pre-clinical DLBCL model. In CD-1 mice, dosing of EED226 for 14 days at 300 mg/kg bid is well tolerated with no apparent adverse effects. It has very low in vivo clearance, and approximately 100% oral bioavailability. EED226 has low volume of distribution (0.8 L/kg), reasonable terminal t1/2 (2.2 h), and moderate plasma protein binding (PPB)[1].
References:
[1]. Huang Y, et al. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. J Med Chem. 2017 Mar 23;60(6):2215-2226.
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *